Shifting Medicine Forward

Our path toward disease-centric therapies

ONCOLOGY
Ichnos continues to advance its pipeline of multispecific antibodies in oncology, with lead asset ISB 1342 in Phase 1, and ISB 1442 in IND-enabling studies. Please contact us at corporate.communications@ichnossciences.com if you are interested in exploring a partnership.
Asset Description Preclinical Phase 1 Phase 2 Phase 3 Status

Products

ISB 1342
CD38 x CD3 BEAT® 1.0 bispecific antibody
Relapsed/Refractory Multiple Myeloma (R/R MM); T-ALL under consideration
      Phase 1 Enrolling
ISB 1442
CD38 x CD47 BEAT® 2.0 bispecific antibody
R/R MM; AML and T-ALL under consideration
      PHASE 1 INITIATION
ISB 2001
BCMA x CD38 x CD3 TREAT™ trispecific antibody
R/R MM
      IND-Enabling Studies

Candidates

ISB 2004
BEAT® 2.0 bispecific antibody
Hematologic Malignancies/ Solid Tumors
      Discovery
ISB 2005
TREAT™ trispecific antibody
Solid Tumors
      Discovery

Products

Compound:
ISB 1342
Target:
CD38 x CD3 BEAT® 1.0 bispecific antibody
Indication:
Relapsed/Refractory Multiple Myeloma (R/R MM); T-ALL under consideration
Phase:
phase-1
Status:
Phase 1 Enrolling
Compound:
ISB 1442
Target:
CD38 x CD47 BEAT® 2.0 bispecific antibody
Indication:
R/R MM; AML and T-ALL under consideration
Phase:
phase-1
Status:
PHASE 1 INITIATION
Compound:
ISB 2001
Target:
BCMA x CD38 x CD3 TREAT™ trispecific antibody
Indication:
R/R MM
Phase:
preclinical
Status:
IND-Enabling Studies

Candidates

Compound:
ISB 2004
Target:
BEAT® 2.0 bispecific antibody
Indication:
Hematologic Malignancies/ Solid Tumors
Phase:
preclinical
Status:
Discovery
Compound:
ISB 2005
Target:
TREAT™ trispecific antibody
Indication:
Solid Tumors
Phase:
preclinical
Status:
Discovery


BEAT®Bispecific Engagement by Antibodies based on the TCR
TREAT™: Trispecific Engagement by Antibodies based on the TCR

 
Autoimmune Disease
Ichnos is out-licensing its autoimmune disease assets to enable greater focus on oncology. Explore the pipeline chart below to learn more and contact us at Corporate.Communications@ichnossciences.com for additional information.
Products Description Preclinical Phase 1 Phase 2 Phase 3 Status
ISB 830 (telazorlimab) (Licensing discussions ongoing)
OX40 antagonist monoclonal antibody
Atopic Dermatitis (AD)*
      Phase 2b completed
ISB 880 (Licensed to Almirall S.A.)
IL-1RAP antagonist monoclonal antibody
Autoimmune Disease
      IND-Enabling Studies Completed
Autoimmune Disease
Compound:
ISB 830 (telazorlimab) (Licensing discussions ongoing)
Target:
OX40 antagonist monoclonal antibody
Indication:
Atopic Dermatitis (AD)*
Phase:
phase-2
Status:
Phase 2b completed
Compound:
ISB 880 (Licensed to Almirall S.A.)
Target:
IL-1RAP antagonist monoclonal antibody
Indication:
Autoimmune Disease
Phase:
preclinical
Status:
IND-Enabling Studies Completed
 

*A US IND for rheumatoid arthritis and other autoimmune indications is active.
Primary efficacy endpoint (EASI score, % change, baseline to week 16) met at two highest doses tested. Numerical improvements were seen for the two higher-dose arms (300 mg and 600 mg q 2 weeks) of telazorlimab compared to placebo in the secondary endpoints of EASI-75 and Investigator Global Assessment, but the differences were generally not statistically significantly different from placebo.

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.